Background: Magnetic resonance imaging (MRI) is a non-invasive imaging modality which, in conjunction with biopsies, provide a qualitative assessment of tumor response to treatment. Intravenous injection of contrast agents such as fluorine (19F) nanoemulsions labels systemic macrophages, which can, then, be tracked in real time with MRI. This method can provide quantifiable insights into the behavior of tumor-associated macrophages (TAMs) in the tumor microenvironment and macrophage recruitment during therapy. Methods: Female mice received mammary fat pad injections of murine breast or colon cancer cell lines. The mice then received an intravenous 19F nanoemulsion injection, followed by a baseline 19F MRI. For each cancer model, half of the mice then received 8 Gy of localized radiation therapy (RT), while others remained untreated. The mice were monitored for two weeks for tumor growth and 9F signal using MRI. Results: Across both cohorts, the RT-treated groups presented significant tumor growth reduction or arrest, contrary to the untreated groups. Similarly, the fluorine signal in treated groups increased significantly as early as four days post therapy. The fluorine signal change correlated to tumor volumes irrespective of time. Conclusion: These results demonstrate the potential of 19F MRI to non-invasively track macrophages during radiation therapy and its prognostic value with regard to tumor growth.
Tracking T cells in vivo using MRI is a major challenge due to the difficulty of labeling these non-phagocytic cells with a sufficient contrast agent to generate a detectable signal change. In this study, we explored CD4-Superparamagnetic iron oxide nanoparticles (SPION), which is commonly used in magnetic cell sorting, as a potential receptor-mediated, specific CD4+ T cell MRI labeling agent. We optimized the labeling protocol for maximal CD4+ cell labeling and viability. Cell health was confirmed with trypan blue assay, and labeling efficacy was confirmed with Prussian blue staining, transmission electron microscopy, and MRI of labeled cell pellets. Key cell functionality was assessed by flow cytometry. Next, CD4-SPION-labeled T cells or unlabeled T cells were delivered via intravenous injection in naïve mice. Liver MRIs pre-, 24 h, and 72 h post-T cell injection were performed to determine in vivo tracking ability. Our results show that CD4-SPION induces significant attenuation of T2 signals in a concentration-dependent manner, confirming their potential as an effective MRI contrast agent. In vitro, analyses showed that CD4+ T cells were able to uptake CD4-SPION without affecting cellular activity and key functions, as evidenced by Prussian blue staining and flow cytometric analysis of IL-2 receptor and the IL-7 receptor α-chains, CD69 upregulation, and IFN-γ secretion. In vivo, systemically distributed CD4-SPION-labeled T cells could be tracked in the liver at 24 and 72 h after injection, contrary to controls. Histological staining of tissue sections validated the findings. Our results showed that SPION CD4+ T cell sorting coupled with longitudinal MR imaging is a valid method to track CD4+ T cells in vivo. This safe, specific, and sensitive approach will facilitate the use of SPION as an MRI contrast agent in clinical practice, allowing for non-invasive tracking of adoptive cell therapies in multiple disease conditions.
Background.: This study aims to evaluate the impact of obesity on post–liver transplant outcomes stratified by low- and high-performance status. Methods.: Patients undergoing liver transplantation between 2006 and 2023 were identified in the United Network for Organ Sharing data set. Patients with severe obesity body mass index ([BMI] ≥40 kg/m2) and super obesity (BMI >50 kg/m2) were compared with those with lower BMI on perioperative and long-term outcomes stratified by preoperative performance status. Results.: Severe obesity has a significant negative impact on perioperative and long-term outcomes on the low-performance group (LPG). This effect was not observed in the high-performance group. Five-year survival in the high-performance group was 81.7%, compared with 77.9% in the LPG. The multivariable analysis revealed that severe obesity in the LPG increased early graft loss by 53%, and 30- and 90-d mortality by 57% and 50%, respectively (P < 0.001). Severe obesity significantly impacted overall graft survival but did not affect long-term patient survival. When advanced age was combined with severe obesity in the LPG, our analysis showed a 2.3-fold increased risk of early graft loss (P = 0.01) and 83%, 90-d perioperative mortality (P < 0.001). Overall long-term graft and patient survival were decreased by 56% and 59%, respectively, in the LPG (P < 0.001). Conclusions.: Severe obesity in patients with a low-performance status before transplantation significantly increases the risk of poor perioperative and long-term outcomes. Interestingly, this effect is not seen in patients with high-performance scores. Additionally, the combination of severe obesity and advanced age in low-performance status patients may have a compounded negative effect on posttransplant survival.